Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT

BACKGROUND: STEPAUT, an Austrian non-interventional study, evaluated the safety and efficacy of everolimus plus exemestane in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) recurring/progressing on/after nonsteroi...

Descripción completa

Detalles Bibliográficos
Autores principales: Steger, Guenther G., Egle, Daniel, Bartsch, Rupert, Pfeiler, Georg, Petru, Edgar, Greil, Richard, Helfgott, Ruth, Marth, Christian, Öhler, Leopold, Hubalek, Michael, Lang, Alois, Tinchon, Christoph, Haslbauer, Ferdinand, Redl, Andreas, Hock, Karin, Hennebelle, Mathias, Mraz, Bernhard, Gnant, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375626/
https://www.ncbi.nlm.nih.gov/pubmed/32062536
http://dx.doi.org/10.1016/j.breast.2020.01.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375626/
https://www.ncbi.nlm.nih.gov/pubmed/32062536
http://dx.doi.org/10.1016/j.breast.2020.01.035

Ejemplares similares